iScience-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2235606, encodeId=556c2235606e6, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：分享记录一下我的投稿经历，希望能帮到大家。 准备投稿的朋友们一定要提前查看资料，做足准备，不然真多很浪费时间，还有一定要留意作者须知，修改时要按照编辑的建议认真修改。 6.3 submitted 6.4 with editor 6.8 under review 7.12 major revision 8.13 revision submitted to journal 8.15 under review 8.24 all reviews complete 8.25 pre-accept 8.27 revision submitted to journal 8.28 with editor 9.13 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822132, createdTime=Wed Nov 06 22:50:05 CST 2024, time=2024-11-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233162, encodeId=f9fc2233162c0, content=7.14 Cell-Press Multi-Journal 投稿(选了Cell Reports和iScience) 7.24 Cell reports拒了，iScience 可以送审，所以当天转投iScience 7.28 送审 8.27 一审意见返回 major revision 10.2 修回 10.15 一审结束 accepted-in-principle 开始改格式 10.15-10.25 从R1改格式改到R5 编辑效率感人！ 10.25 正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f57a5273929, createdName=1482b61bm01暂无昵称, createdTime=Fri Oct 25 18:53:29 CST 2024, time=2024-10-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2236611, encodeId=1fee223661196, content=审稿速度:1.0 偏重的研究方向：药物;医学综合 经验分享：iScience影响因子不会又往下掉吧……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Tue Nov 12 23:12:36 CST 2024, time=2024-11-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;蛋白组 经验分享：2024年2月16投稿 2024年3月18小修 2024年3月29修回，等得都想催稿了 2024年4月24原则性接收，开始改格式，改了三四次格式 2024年5月09接收 感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2233171, encodeId=f09f22331e1ac, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：准备投稿的小伙伴可以了解一下，效率很高，编辑也很好沟通，比较有耐心。还有一定要留意作者须知。 5.6 with editor 5.9 under review 6.14 major revision 7.15 revision submitted to journal 7.17 under review 7.24 all reviews complete 7.26 pre-accept 7.28 revision submitted to journal 7.29 with editor 8.14 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 21:51:05 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233777, encodeId=215a2233e7794, content=24/8/25投稿的现在还是under review 啊啊啊等着找工作好愁求求给个机会吧什么时候可以催稿呢而且这个系统是不是看不出邀请审稿人的进度o或者是进入该阶段的时间只能看到投稿的初始时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/4514a8c32113e39f47fc3ca88f48c884.jpg, createdBy=04065087347, createdName=跑跑啊啊啊啊, createdTime=Mon Oct 28 22:57:10 CST 2024, time=2024-10-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省)]

2024-11-06 ms1000001788822132 来自上海

审稿速度:2.0 | 投稿命中率:75.0
经验分享：分享记录一下我的投稿经历，希望能帮到大家。
准备投稿的朋友们一定要提前查看资料，做足准备，不然真多很浪费时间，还有一定要留意作者须知，修改时要按照编辑的建议认真修改。
6.3 submitted
6.4 with editor
6.8 under review
7.12 major revision
8.13 revision submitted to journal
8.15 under review
8.24 all reviews complete
8.25 pre-accept
8.27 revision submitted to journal
8.28 with editor
9.13 accept

17 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2235606, encodeId=556c2235606e6, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：分享记录一下我的投稿经历，希望能帮到大家。 准备投稿的朋友们一定要提前查看资料，做足准备，不然真多很浪费时间，还有一定要留意作者须知，修改时要按照编辑的建议认真修改。 6.3 submitted 6.4 with editor 6.8 under review 7.12 major revision 8.13 revision submitted to journal 8.15 under review 8.24 all reviews complete 8.25 pre-accept 8.27 revision submitted to journal 8.28 with editor 9.13 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822132, createdTime=Wed Nov 06 22:50:05 CST 2024, time=2024-11-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233162, encodeId=f9fc2233162c0, content=7.14 Cell-Press Multi-Journal 投稿(选了Cell Reports和iScience) 7.24 Cell reports拒了，iScience 可以送审，所以当天转投iScience 7.28 送审 8.27 一审意见返回 major revision 10.2 修回 10.15 一审结束 accepted-in-principle 开始改格式 10.15-10.25 从R1改格式改到R5 编辑效率感人！ 10.25 正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f57a5273929, createdName=1482b61bm01暂无昵称, createdTime=Fri Oct 25 18:53:29 CST 2024, time=2024-10-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2236611, encodeId=1fee223661196, content=审稿速度:1.0 偏重的研究方向：药物;医学综合 经验分享：iScience影响因子不会又往下掉吧……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Tue Nov 12 23:12:36 CST 2024, time=2024-11-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;蛋白组 经验分享：2024年2月16投稿 2024年3月18小修 2024年3月29修回，等得都想催稿了 2024年4月24原则性接收，开始改格式，改了三四次格式 2024年5月09接收 感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2233171, encodeId=f09f22331e1ac, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：准备投稿的小伙伴可以了解一下，效率很高，编辑也很好沟通，比较有耐心。还有一定要留意作者须知。 5.6 with editor 5.9 under review 6.14 major revision 7.15 revision submitted to journal 7.17 under review 7.24 all reviews complete 7.26 pre-accept 7.28 revision submitted to journal 7.29 with editor 8.14 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 21:51:05 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233777, encodeId=215a2233e7794, content=24/8/25投稿的现在还是under review 啊啊啊等着找工作好愁求求给个机会吧什么时候可以催稿呢而且这个系统是不是看不出邀请审稿人的进度o或者是进入该阶段的时间只能看到投稿的初始时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/4514a8c32113e39f47fc3ca88f48c884.jpg, createdBy=04065087347, createdName=跑跑啊啊啊啊, createdTime=Mon Oct 28 22:57:10 CST 2024, time=2024-10-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省)]

2024-10-25 1482b61bm01暂无昵称来自福建省

7.14 Cell-Press Multi-Journal 投稿(选了Cell Reports和iScience) 7.24 Cell reports拒了，iScience 可以送审，所以当天转投iScience 7.28 送审 8.27 一审意见返回 major revision 10.2 修回 10.15 一审结束 accepted-in-principle 开始改格式 10.15-10.25 从R1改格式改到R5 编辑效率感人！ 10.25 正式接收

27 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2235606, encodeId=556c2235606e6, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：分享记录一下我的投稿经历，希望能帮到大家。 准备投稿的朋友们一定要提前查看资料，做足准备，不然真多很浪费时间，还有一定要留意作者须知，修改时要按照编辑的建议认真修改。 6.3 submitted 6.4 with editor 6.8 under review 7.12 major revision 8.13 revision submitted to journal 8.15 under review 8.24 all reviews complete 8.25 pre-accept 8.27 revision submitted to journal 8.28 with editor 9.13 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822132, createdTime=Wed Nov 06 22:50:05 CST 2024, time=2024-11-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233162, encodeId=f9fc2233162c0, content=7.14 Cell-Press Multi-Journal 投稿(选了Cell Reports和iScience) 7.24 Cell reports拒了，iScience 可以送审，所以当天转投iScience 7.28 送审 8.27 一审意见返回 major revision 10.2 修回 10.15 一审结束 accepted-in-principle 开始改格式 10.15-10.25 从R1改格式改到R5 编辑效率感人！ 10.25 正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f57a5273929, createdName=1482b61bm01暂无昵称, createdTime=Fri Oct 25 18:53:29 CST 2024, time=2024-10-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2236611, encodeId=1fee223661196, content=审稿速度:1.0 偏重的研究方向：药物;医学综合 经验分享：iScience影响因子不会又往下掉吧……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Tue Nov 12 23:12:36 CST 2024, time=2024-11-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;蛋白组 经验分享：2024年2月16投稿 2024年3月18小修 2024年3月29修回，等得都想催稿了 2024年4月24原则性接收，开始改格式，改了三四次格式 2024年5月09接收 感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2233171, encodeId=f09f22331e1ac, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：准备投稿的小伙伴可以了解一下，效率很高，编辑也很好沟通，比较有耐心。还有一定要留意作者须知。 5.6 with editor 5.9 under review 6.14 major revision 7.15 revision submitted to journal 7.17 under review 7.24 all reviews complete 7.26 pre-accept 7.28 revision submitted to journal 7.29 with editor 8.14 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 21:51:05 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233777, encodeId=215a2233e7794, content=24/8/25投稿的现在还是under review 啊啊啊等着找工作好愁求求给个机会吧什么时候可以催稿呢而且这个系统是不是看不出邀请审稿人的进度o或者是进入该阶段的时间只能看到投稿的初始时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/4514a8c32113e39f47fc3ca88f48c884.jpg, createdBy=04065087347, createdName=跑跑啊啊啊啊, createdTime=Mon Oct 28 22:57:10 CST 2024, time=2024-10-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省)]

2024-11-12 少吃一口来自四川省

审稿速度:1.0
偏重的研究方向：药物;医学综合
经验分享：iScience影响因子不会又往下掉吧……

9 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2235606, encodeId=556c2235606e6, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：分享记录一下我的投稿经历，希望能帮到大家。 准备投稿的朋友们一定要提前查看资料，做足准备，不然真多很浪费时间，还有一定要留意作者须知，修改时要按照编辑的建议认真修改。 6.3 submitted 6.4 with editor 6.8 under review 7.12 major revision 8.13 revision submitted to journal 8.15 under review 8.24 all reviews complete 8.25 pre-accept 8.27 revision submitted to journal 8.28 with editor 9.13 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822132, createdTime=Wed Nov 06 22:50:05 CST 2024, time=2024-11-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233162, encodeId=f9fc2233162c0, content=7.14 Cell-Press Multi-Journal 投稿(选了Cell Reports和iScience) 7.24 Cell reports拒了，iScience 可以送审，所以当天转投iScience 7.28 送审 8.27 一审意见返回 major revision 10.2 修回 10.15 一审结束 accepted-in-principle 开始改格式 10.15-10.25 从R1改格式改到R5 编辑效率感人！ 10.25 正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f57a5273929, createdName=1482b61bm01暂无昵称, createdTime=Fri Oct 25 18:53:29 CST 2024, time=2024-10-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2236611, encodeId=1fee223661196, content=审稿速度:1.0 偏重的研究方向：药物;医学综合 经验分享：iScience影响因子不会又往下掉吧……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Tue Nov 12 23:12:36 CST 2024, time=2024-11-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;蛋白组 经验分享：2024年2月16投稿 2024年3月18小修 2024年3月29修回，等得都想催稿了 2024年4月24原则性接收，开始改格式，改了三四次格式 2024年5月09接收 感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2233171, encodeId=f09f22331e1ac, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：准备投稿的小伙伴可以了解一下，效率很高，编辑也很好沟通，比较有耐心。还有一定要留意作者须知。 5.6 with editor 5.9 under review 6.14 major revision 7.15 revision submitted to journal 7.17 under review 7.24 all reviews complete 7.26 pre-accept 7.28 revision submitted to journal 7.29 with editor 8.14 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 21:51:05 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233777, encodeId=215a2233e7794, content=24/8/25投稿的现在还是under review 啊啊啊等着找工作好愁求求给个机会吧什么时候可以催稿呢而且这个系统是不是看不出邀请审稿人的进度o或者是进入该阶段的时间只能看到投稿的初始时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/4514a8c32113e39f47fc3ca88f48c884.jpg, createdBy=04065087347, createdName=跑跑啊啊啊啊, createdTime=Mon Oct 28 22:57:10 CST 2024, time=2024-10-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省)]

2024-08-04 少吃一口来自四川省

偏重的研究方向：免疫学;医学综合
经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些

0 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2235606, encodeId=556c2235606e6, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：分享记录一下我的投稿经历，希望能帮到大家。 准备投稿的朋友们一定要提前查看资料，做足准备，不然真多很浪费时间，还有一定要留意作者须知，修改时要按照编辑的建议认真修改。 6.3 submitted 6.4 with editor 6.8 under review 7.12 major revision 8.13 revision submitted to journal 8.15 under review 8.24 all reviews complete 8.25 pre-accept 8.27 revision submitted to journal 8.28 with editor 9.13 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822132, createdTime=Wed Nov 06 22:50:05 CST 2024, time=2024-11-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233162, encodeId=f9fc2233162c0, content=7.14 Cell-Press Multi-Journal 投稿(选了Cell Reports和iScience) 7.24 Cell reports拒了，iScience 可以送审，所以当天转投iScience 7.28 送审 8.27 一审意见返回 major revision 10.2 修回 10.15 一审结束 accepted-in-principle 开始改格式 10.15-10.25 从R1改格式改到R5 编辑效率感人！ 10.25 正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f57a5273929, createdName=1482b61bm01暂无昵称, createdTime=Fri Oct 25 18:53:29 CST 2024, time=2024-10-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2236611, encodeId=1fee223661196, content=审稿速度:1.0 偏重的研究方向：药物;医学综合 经验分享：iScience影响因子不会又往下掉吧……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Tue Nov 12 23:12:36 CST 2024, time=2024-11-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;蛋白组 经验分享：2024年2月16投稿 2024年3月18小修 2024年3月29修回，等得都想催稿了 2024年4月24原则性接收，开始改格式，改了三四次格式 2024年5月09接收 感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2233171, encodeId=f09f22331e1ac, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：准备投稿的小伙伴可以了解一下，效率很高，编辑也很好沟通，比较有耐心。还有一定要留意作者须知。 5.6 with editor 5.9 under review 6.14 major revision 7.15 revision submitted to journal 7.17 under review 7.24 all reviews complete 7.26 pre-accept 7.28 revision submitted to journal 7.29 with editor 8.14 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 21:51:05 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233777, encodeId=215a2233e7794, content=24/8/25投稿的现在还是under review 啊啊啊等着找工作好愁求求给个机会吧什么时候可以催稿呢而且这个系统是不是看不出邀请审稿人的进度o或者是进入该阶段的时间只能看到投稿的初始时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/4514a8c32113e39f47fc3ca88f48c884.jpg, createdBy=04065087347, createdName=跑跑啊啊啊啊, createdTime=Mon Oct 28 22:57:10 CST 2024, time=2024-10-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省)]

2024-10-16 ms3000001892618058 来自湖北省

二审两个多月了，还没消息，有一样的小伙伴吗？

24 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2235606, encodeId=556c2235606e6, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：分享记录一下我的投稿经历，希望能帮到大家。 准备投稿的朋友们一定要提前查看资料，做足准备，不然真多很浪费时间，还有一定要留意作者须知，修改时要按照编辑的建议认真修改。 6.3 submitted 6.4 with editor 6.8 under review 7.12 major revision 8.13 revision submitted to journal 8.15 under review 8.24 all reviews complete 8.25 pre-accept 8.27 revision submitted to journal 8.28 with editor 9.13 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822132, createdTime=Wed Nov 06 22:50:05 CST 2024, time=2024-11-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233162, encodeId=f9fc2233162c0, content=7.14 Cell-Press Multi-Journal 投稿(选了Cell Reports和iScience) 7.24 Cell reports拒了，iScience 可以送审，所以当天转投iScience 7.28 送审 8.27 一审意见返回 major revision 10.2 修回 10.15 一审结束 accepted-in-principle 开始改格式 10.15-10.25 从R1改格式改到R5 编辑效率感人！ 10.25 正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f57a5273929, createdName=1482b61bm01暂无昵称, createdTime=Fri Oct 25 18:53:29 CST 2024, time=2024-10-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2236611, encodeId=1fee223661196, content=审稿速度:1.0 偏重的研究方向：药物;医学综合 经验分享：iScience影响因子不会又往下掉吧……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Tue Nov 12 23:12:36 CST 2024, time=2024-11-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;蛋白组 经验分享：2024年2月16投稿 2024年3月18小修 2024年3月29修回，等得都想催稿了 2024年4月24原则性接收，开始改格式，改了三四次格式 2024年5月09接收 感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2233171, encodeId=f09f22331e1ac, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：准备投稿的小伙伴可以了解一下，效率很高，编辑也很好沟通，比较有耐心。还有一定要留意作者须知。 5.6 with editor 5.9 under review 6.14 major revision 7.15 revision submitted to journal 7.17 under review 7.24 all reviews complete 7.26 pre-accept 7.28 revision submitted to journal 7.29 with editor 8.14 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 21:51:05 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233777, encodeId=215a2233e7794, content=24/8/25投稿的现在还是under review 啊啊啊等着找工作好愁求求给个机会吧什么时候可以催稿呢而且这个系统是不是看不出邀请审稿人的进度o或者是进入该阶段的时间只能看到投稿的初始时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/4514a8c32113e39f47fc3ca88f48c884.jpg, createdBy=04065087347, createdName=跑跑啊啊啊啊, createdTime=Mon Oct 28 22:57:10 CST 2024, time=2024-10-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省)]

2024-05-09 ms2000000185262432 来自广西

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤;蛋白组
经验分享：2024年2月16投稿
2024年3月18小修
2024年3月29修回，等得都想催稿了
2024年4月24原则性接收，开始改格式，改了三四次格式
2024年5月09接收
感谢iscience的认可，兄弟们加油

92 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2235606, encodeId=556c2235606e6, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：分享记录一下我的投稿经历，希望能帮到大家。 准备投稿的朋友们一定要提前查看资料，做足准备，不然真多很浪费时间，还有一定要留意作者须知，修改时要按照编辑的建议认真修改。 6.3 submitted 6.4 with editor 6.8 under review 7.12 major revision 8.13 revision submitted to journal 8.15 under review 8.24 all reviews complete 8.25 pre-accept 8.27 revision submitted to journal 8.28 with editor 9.13 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822132, createdTime=Wed Nov 06 22:50:05 CST 2024, time=2024-11-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233162, encodeId=f9fc2233162c0, content=7.14 Cell-Press Multi-Journal 投稿(选了Cell Reports和iScience) 7.24 Cell reports拒了，iScience 可以送审，所以当天转投iScience 7.28 送审 8.27 一审意见返回 major revision 10.2 修回 10.15 一审结束 accepted-in-principle 开始改格式 10.15-10.25 从R1改格式改到R5 编辑效率感人！ 10.25 正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f57a5273929, createdName=1482b61bm01暂无昵称, createdTime=Fri Oct 25 18:53:29 CST 2024, time=2024-10-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2236611, encodeId=1fee223661196, content=审稿速度:1.0 偏重的研究方向：药物;医学综合 经验分享：iScience影响因子不会又往下掉吧……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Tue Nov 12 23:12:36 CST 2024, time=2024-11-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;蛋白组 经验分享：2024年2月16投稿 2024年3月18小修 2024年3月29修回，等得都想催稿了 2024年4月24原则性接收，开始改格式，改了三四次格式 2024年5月09接收 感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2233171, encodeId=f09f22331e1ac, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：准备投稿的小伙伴可以了解一下，效率很高，编辑也很好沟通，比较有耐心。还有一定要留意作者须知。 5.6 with editor 5.9 under review 6.14 major revision 7.15 revision submitted to journal 7.17 under review 7.24 all reviews complete 7.26 pre-accept 7.28 revision submitted to journal 7.29 with editor 8.14 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 21:51:05 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233777, encodeId=215a2233e7794, content=24/8/25投稿的现在还是under review 啊啊啊等着找工作好愁求求给个机会吧什么时候可以催稿呢而且这个系统是不是看不出邀请审稿人的进度o或者是进入该阶段的时间只能看到投稿的初始时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/4514a8c32113e39f47fc3ca88f48c884.jpg, createdBy=04065087347, createdName=跑跑啊啊啊啊, createdTime=Mon Oct 28 22:57:10 CST 2024, time=2024-10-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省)]

2024-10-25 ms1000001788822128 来自北京

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤
经验分享：准备投稿的小伙伴可以了解一下，效率很高，编辑也很好沟通，比较有耐心。还有一定要留意作者须知。
5.6 with editor
5.9 under review
6.14 major revision
7.15 revision submitted to journal
7.17 under review
7.24 all reviews complete
7.26 pre-accept
7.28 revision submitted to journal
7.29 with editor
8.14 accept

22 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2235606, encodeId=556c2235606e6, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：分享记录一下我的投稿经历，希望能帮到大家。 准备投稿的朋友们一定要提前查看资料，做足准备，不然真多很浪费时间，还有一定要留意作者须知，修改时要按照编辑的建议认真修改。 6.3 submitted 6.4 with editor 6.8 under review 7.12 major revision 8.13 revision submitted to journal 8.15 under review 8.24 all reviews complete 8.25 pre-accept 8.27 revision submitted to journal 8.28 with editor 9.13 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822132, createdTime=Wed Nov 06 22:50:05 CST 2024, time=2024-11-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233162, encodeId=f9fc2233162c0, content=7.14 Cell-Press Multi-Journal 投稿(选了Cell Reports和iScience) 7.24 Cell reports拒了，iScience 可以送审，所以当天转投iScience 7.28 送审 8.27 一审意见返回 major revision 10.2 修回 10.15 一审结束 accepted-in-principle 开始改格式 10.15-10.25 从R1改格式改到R5 编辑效率感人！ 10.25 正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f57a5273929, createdName=1482b61bm01暂无昵称, createdTime=Fri Oct 25 18:53:29 CST 2024, time=2024-10-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2236611, encodeId=1fee223661196, content=审稿速度:1.0 偏重的研究方向：药物;医学综合 经验分享：iScience影响因子不会又往下掉吧……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Tue Nov 12 23:12:36 CST 2024, time=2024-11-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;蛋白组 经验分享：2024年2月16投稿 2024年3月18小修 2024年3月29修回，等得都想催稿了 2024年4月24原则性接收，开始改格式，改了三四次格式 2024年5月09接收 感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2233171, encodeId=f09f22331e1ac, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：准备投稿的小伙伴可以了解一下，效率很高，编辑也很好沟通，比较有耐心。还有一定要留意作者须知。 5.6 with editor 5.9 under review 6.14 major revision 7.15 revision submitted to journal 7.17 under review 7.24 all reviews complete 7.26 pre-accept 7.28 revision submitted to journal 7.29 with editor 8.14 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 21:51:05 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233777, encodeId=215a2233e7794, content=24/8/25投稿的现在还是under review 啊啊啊等着找工作好愁求求给个机会吧什么时候可以催稿呢而且这个系统是不是看不出邀请审稿人的进度o或者是进入该阶段的时间只能看到投稿的初始时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/4514a8c32113e39f47fc3ca88f48c884.jpg, createdBy=04065087347, createdName=跑跑啊啊啊啊, createdTime=Mon Oct 28 22:57:10 CST 2024, time=2024-10-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省)]

2024-10-28 跑跑啊啊啊啊来自上海

24/8/25投稿的现在还是under review 啊啊啊等着找工作好愁求求给个机会吧什么时候可以催稿呢而且这个系统是不是看不出邀请审稿人的进度o或者是进入该阶段的时间只能看到投稿的初始时间

18 0

[GetPortalCommentsPageByObjectIdResponse(id=2235606, encodeId=556c2235606e6, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：分享记录一下我的投稿经历，希望能帮到大家。 准备投稿的朋友们一定要提前查看资料，做足准备，不然真多很浪费时间，还有一定要留意作者须知，修改时要按照编辑的建议认真修改。 6.3 submitted 6.4 with editor 6.8 under review 7.12 major revision 8.13 revision submitted to journal 8.15 under review 8.24 all reviews complete 8.25 pre-accept 8.27 revision submitted to journal 8.28 with editor 9.13 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822132, createdTime=Wed Nov 06 22:50:05 CST 2024, time=2024-11-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233162, encodeId=f9fc2233162c0, content=7.14 Cell-Press Multi-Journal 投稿(选了Cell Reports和iScience) 7.24 Cell reports拒了，iScience 可以送审，所以当天转投iScience 7.28 送审 8.27 一审意见返回 major revision 10.2 修回 10.15 一审结束 accepted-in-principle 开始改格式 10.15-10.25 从R1改格式改到R5 编辑效率感人！ 10.25 正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f57a5273929, createdName=1482b61bm01暂无昵称, createdTime=Fri Oct 25 18:53:29 CST 2024, time=2024-10-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2236611, encodeId=1fee223661196, content=审稿速度:1.0 偏重的研究方向：药物;医学综合 经验分享：iScience影响因子不会又往下掉吧……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Tue Nov 12 23:12:36 CST 2024, time=2024-11-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;蛋白组 经验分享：2024年2月16投稿 2024年3月18小修 2024年3月29修回，等得都想催稿了 2024年4月24原则性接收，开始改格式，改了三四次格式 2024年5月09接收 感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2233171, encodeId=f09f22331e1ac, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：准备投稿的小伙伴可以了解一下，效率很高，编辑也很好沟通，比较有耐心。还有一定要留意作者须知。 5.6 with editor 5.9 under review 6.14 major revision 7.15 revision submitted to journal 7.17 under review 7.24 all reviews complete 7.26 pre-accept 7.28 revision submitted to journal 7.29 with editor 8.14 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 21:51:05 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233777, encodeId=215a2233e7794, content=24/8/25投稿的现在还是under review 啊啊啊等着找工作好愁求求给个机会吧什么时候可以催稿呢而且这个系统是不是看不出邀请审稿人的进度o或者是进入该阶段的时间只能看到投稿的初始时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/4514a8c32113e39f47fc3ca88f48c884.jpg, createdBy=04065087347, createdName=跑跑啊啊啊啊, createdTime=Mon Oct 28 22:57:10 CST 2024, time=2024-10-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省)]

2024-06-03 ms4000001339792170 来自湖北省

审稿速度:1.0
经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，

86 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2235606, encodeId=556c2235606e6, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：分享记录一下我的投稿经历，希望能帮到大家。 准备投稿的朋友们一定要提前查看资料，做足准备，不然真多很浪费时间，还有一定要留意作者须知，修改时要按照编辑的建议认真修改。 6.3 submitted 6.4 with editor 6.8 under review 7.12 major revision 8.13 revision submitted to journal 8.15 under review 8.24 all reviews complete 8.25 pre-accept 8.27 revision submitted to journal 8.28 with editor 9.13 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822132, createdTime=Wed Nov 06 22:50:05 CST 2024, time=2024-11-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233162, encodeId=f9fc2233162c0, content=7.14 Cell-Press Multi-Journal 投稿(选了Cell Reports和iScience) 7.24 Cell reports拒了，iScience 可以送审，所以当天转投iScience 7.28 送审 8.27 一审意见返回 major revision 10.2 修回 10.15 一审结束 accepted-in-principle 开始改格式 10.15-10.25 从R1改格式改到R5 编辑效率感人！ 10.25 正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f57a5273929, createdName=1482b61bm01暂无昵称, createdTime=Fri Oct 25 18:53:29 CST 2024, time=2024-10-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2236611, encodeId=1fee223661196, content=审稿速度:1.0 偏重的研究方向：药物;医学综合 经验分享：iScience影响因子不会又往下掉吧……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Tue Nov 12 23:12:36 CST 2024, time=2024-11-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;蛋白组 经验分享：2024年2月16投稿 2024年3月18小修 2024年3月29修回，等得都想催稿了 2024年4月24原则性接收，开始改格式，改了三四次格式 2024年5月09接收 感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2233171, encodeId=f09f22331e1ac, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：准备投稿的小伙伴可以了解一下，效率很高，编辑也很好沟通，比较有耐心。还有一定要留意作者须知。 5.6 with editor 5.9 under review 6.14 major revision 7.15 revision submitted to journal 7.17 under review 7.24 all reviews complete 7.26 pre-accept 7.28 revision submitted to journal 7.29 with editor 8.14 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 21:51:05 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233777, encodeId=215a2233e7794, content=24/8/25投稿的现在还是under review 啊啊啊等着找工作好愁求求给个机会吧什么时候可以催稿呢而且这个系统是不是看不出邀请审稿人的进度o或者是进入该阶段的时间只能看到投稿的初始时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/4514a8c32113e39f47fc3ca88f48c884.jpg, createdBy=04065087347, createdName=跑跑啊啊啊啊, createdTime=Mon Oct 28 22:57:10 CST 2024, time=2024-10-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省)]

2024-08-27 ms2000000368944021 来自湖南省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：分子生物
经验分享：all reviews complete要多久呀

0 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务